SynaptixBio: Funding, Investors & Team (Oct 2026)
Summary SynaptixBio is a biotech company focused on developing innovative treatments for severe childhood neurodegenerative diseases, particularly leukodystrophies. Their objective is to utilize gene therapies to combat these fatal disorders resulting from mutations in a single gene. Through the application of antisense oligonucleotide (ASO) technologies, SynaptixBio aims to silence the expression of these harmful genes, effectively halting disease progression and potentially saving lives.
SynaptixBio has raised $17.0M across 3 funding rounds on record, the most recent an undisclosed round of $2.6M announced in Aug 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SynaptixBio Company Profile and Key Stats
Latest funding round on record: Aug 2024.
SynaptixBio Funding Rounds
SynaptixBio raised $13.8M in a Series A announced in Apr 2023.
7 months later, an undisclosed round of $610k was announced in Nov 2023.
9 months later, an undisclosed round of $2.6M was announced in Aug 2024.
SynaptixBio Founders and Leadership Team
No contact details are on record for this team yet.
SynaptixBio Funding Compared to Other Biotechnology Startups
SynaptixBio's latest round of $2.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SynaptixBio in Biotechnology and Oxford
Companies Similar to SynaptixBio
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
SynaptixBio Funding FAQs
What does SynaptixBio do?
Summary SynaptixBio is a biotech company focused on developing innovative treatments for severe childhood neurodegenerative diseases, particularly leukodystrophies. Their objective is to utilize gene therapies to combat these fatal disorders resulting from mutations in a single gene. Through the application of antisense oligonucleotide (ASO) technologies, SynaptixBio aims to silence the expression of these harmful genes, effectively halting disease progression and potentially saving lives.
How much funding has SynaptixBio raised?
SynaptixBio has raised $17.0M across 3 rounds on record. The most recent is an undisclosed round of $2.6M announced in Aug 2024.
When did SynaptixBio last raise funding?
SynaptixBio's most recent funding round on record is an undisclosed round of $2.6M, announced in Aug 2024.
Who founded SynaptixBio?
FundedIQ lists Bent Jakobsen (Founder) at SynaptixBio.
Where is SynaptixBio headquartered?
SynaptixBio is based in Oxford, Oxfordshire, United Kingdom.
How many employees does SynaptixBio have?
SynaptixBio is in the 1-10 employee band.
How does SynaptixBio's funding compare to other Biotechnology startups?
SynaptixBio's latest round of $2.6M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's SynaptixBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SynaptixBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.